Get notified when VRXA files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Material Weakness (new) — The company discloses a material weakness in its internal controls over financial reporting, which could lead to errors in financial statements.
  • Going Concern (new) — The SPAC's audited financials raise substantial doubt about its ability to continue as a going concern, with a mandatory liquidation date of August 12, 2026.
  • Related-party Transactions (new) — The company has significant related party transactions with Xlife Sciences AG, including consulting fees, a share lending agreement, and an unsecured loan.
NASDAQ: VRXA Veraxa Biotech Holding AG 424B5

Veraxa Biotech Holding AG, a Swiss oncology biotech, goes public via SPAC merger with Voyager Acquisition Corp.; terms not priced in this 424B5 filing

Filed August 10, 2026 · ~2 min read

Key Changes

  • high

    The company reported a GAAP net loss of CHF 66.6 million for 2025, up from CHF 28.1 million in 2024, driven by a surge in stock-based compensation.

    Risk Factors verify on EDGAR →
  • high

    Stock-based compensation expense jumped to CHF 52.7 million in 2025 from CHF 18.3 million in 2024, mainly due to a higher stock price input in valuation models.

    Notes to Consolidated Financial Statements verify on EDGAR →
  • high

    As of December 31, 2025, the company had only CHF 1.6 million in unrestricted cash and a net working capital deficit of CHF 3.7 million, but management concluded no substantial doubt about going concern after post-year-end financing.

    Risk Factors verify on EDGAR →

5 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (SRBK 10-K) is open in full — no account needed.

Partner

Trade VRXA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify